AIM ImmunoTech (AIM) Other financing activities (2026)

AIM ImmunoTech's (AIM) quarterly Other financing activities came in at $2.2 million in Q1 2026.

AIM ImmunoTech (AIM) Other financing activities (2026) Analysis & Trends

AIM ImmunoTech (AIM) has 1 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.35 Bn	131.49 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.24 Bn	78.25 Bn	3.93 Bn
3	Argenx Se	65.26 Bn	60.08 Bn	1.37 Bn
4	Moderna	58.83 Bn	53.69 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.44 Bn	-
10	AIM ImmunoTech	4.47 Mn	-5.49 Mn	21,000.00

Download Data